Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02145143 · ClinicalTrials.gov registry record · Early Phase 1
Enhancing Radioiodine (RAI) Incorporation Into BRAF Mutant, RAI-Refractory Thyroid Cancers With the BRAF Inhibitor Vemurafenib: A Pilot Study
A Early Phase 1 study of Thyroid Carcinoma, sponsored by Memorial Sloan Kettering Cancer Center.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 12
- Enrollment target
- 1
- Study location
NCT02145143 is a Early Phase 1 study of Thyroid Carcinoma that has completed, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 12 participants. The trial reports 1 study location across 1 state.
The verdict
NCT02145143, a Early Phase 1 study of Thyroid Carcinoma, has completed, sponsored by Memorial Sloan Kettering Cancer Center.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 12 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to find out what effects, good and/or bad, a drug called vemurafenib, either alone or combined with another treatment called radioactive iodine, has on the patient and thyroid cancer. It is not known if vemurafenib works against thyroid cancer. This study will test in a small number of patients if it can be used with radioactive iodine to treat thyroid cancers. This type of study is called a pilot study. If the results are positive, a larger study with more patients may be done to further test this treatment.
Conditions Studied
Interventions
- DRUG Vemurafenib
- DEVICE serial 124I PET/CT
- DRUG thyrotropin alpha
Study Locations (1)
New York
- Memorial Sloan Kettering Cancer Center - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2014-05-20 |
| Est. Completion | 2024-11-21 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02145143
The ClinicalTrials.gov registry entry for NCT02145143 describes a study currently listed as completed, categorized as Early Phase 1. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Memorial Sloan Kettering Cancer Center, which has 1,884 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Thyroid Carcinoma appearing as the primary indexed condition, and to 3 interventions - of which Vemurafenib is the first listed.
NCT02145143 reports 1 study location spanning 1 distinct geographic area - top geographies include New York.
Frequently Asked Questions
What is clinical trial NCT02145143 about?
NCT02145143 is a clinical study titled "Enhancing Radioiodine (RAI) Incorporation Into BRAF Mutant, RAI-Refractory Thyroid Cancers With the BRAF Inhibitor Vemurafenib: A Pilot Study". The purpose of this study is to find out what effects, good and/or bad, a drug called vemurafenib, either alone or combined with another treatment called radioactive iodine, has on the patient and thyroid cancer. It is not known if vemurafenib works against thyroid cancer. This study will test in a ...
What is the current status of trial NCT02145143?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 12 participants. The study started on 2014-05-20. Estimated completion is 2024-11-21.
What conditions does trial NCT02145143 study?
This clinical trial studies the following conditions: Thyroid Carcinoma.
What interventions are being tested in trial NCT02145143?
The interventions under investigation include: Vemurafenib (DRUG), serial 124I PET/CT (DEVICE), thyrotropin alpha (DRUG).
Who is sponsoring clinical trial NCT02145143?
This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02145143 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Thyroid Carcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.